These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 17535864

  • 1. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, Preiss R, Teichert J, Strasburger CJ, Bidlingmaier M.
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [Abstract] [Full Text] [Related]

  • 2. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE, Scanniffio D, Bonomo SM, Cella SG, Sartorio A, Müller EE.
    Neuroendocrinology; 2004 Jun; 79(5):237-46. PubMed ID: 15218318
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 4. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J.
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [Abstract] [Full Text] [Related]

  • 5. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
    Laursen T, Grandjean B, Jørgensen JO, Christiansen JS.
    Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
    [Abstract] [Full Text] [Related]

  • 6. Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults.
    Giannoulis MG, Boroujerdi MA, Powrie J, Dall R, Napoli R, Ehrnborg C, Pentecost C, Cittadini A, Jørgensen JO, Sonksen PH, GH-2000 Study Group.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):315-22. PubMed ID: 15730413
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016 Mar; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency.
    Aimaretti G, Fanciulli G, Bellone S, Maccario M, Arvat E, Delitala G, Camanni F, Ghigo E.
    Eur J Endocrinol; 2001 Sep; 145(3):267-72. PubMed ID: 11517006
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 10. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
    Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
    [Abstract] [Full Text] [Related]

  • 11. Biomarker detection of rhGH doping: an excretion study.
    Jing J, Zhou X, He C, Zhang L, Yang S, Xu Y, Xie M, Yan Y, Su H, Wu M.
    Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial.
    Langbakke IH, Nielsen JN, Skettrup MP, Harper A, Klitgaard T, Weil A, Engelhardt E, Lange M.
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):776-83. PubMed ID: 17634080
    [Abstract] [Full Text] [Related]

  • 13. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.
    Wilson ME.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):4013-21. PubMed ID: 9814485
    [Abstract] [Full Text] [Related]

  • 14. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis.
    Stanhope R, Sörgel F, Gravel P, Pannatier Schuetz YB, Zabransky M, Muenzberg M.
    J Clin Pharmacol; 2010 Nov; 50(11):1339-48. PubMed ID: 20173088
    [Abstract] [Full Text] [Related]

  • 15. Impact of moderate interval exercise versus supine rest on the pharmacokinetics and pharmacodynamic profiles of subcutaneously administered growth hormone in adult growth hormone deficient patients.
    Janukonytė J, Parkner T, Lauritzen T, Christiansen JS, Frystyk J, Pedersen HS, Laursen T.
    Growth Horm IGF Res; 2014 Oct; 24(5):198-204. PubMed ID: 25037883
    [Abstract] [Full Text] [Related]

  • 16. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
    Ehrnborg C, Lange KH, Dall R, Christiansen JS, Lundberg PA, Baxter RC, Boroujerdi MA, Bengtsson BA, Healey ML, Pentecost C, Longobardi S, Napoli R, Rosén T, GH-2000 Study Group.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
    [Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
    Sun YN, Lee HJ, Almon RR, Jusko WJ.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
    [Abstract] [Full Text] [Related]

  • 18. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
    Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
    [Abstract] [Full Text] [Related]

  • 20. Broad variability in pharmacokinetics of GH following rhGH injections in children.
    Lundberg E, Andersson B, Kriström B, Rosberg S, Albertsson-Wikland K.
    Growth Horm IGF Res; 2018 Jun; 40():61-68. PubMed ID: 29422321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.